Racial/ethnic Disparities Not Observed in Clinical Outcomes with Remdesivir Treatment.

배경 Remdesivir (RDV) has demonstrated potent in vitro and in vivo activity against SARS-CoV-2 and favorable clinical efficacy and tolerability in patients with COVID-19. We conducted a randomized, open-label, phase 3 trial of RDV in patients with severe COVID-19. Here we report correlations between race/ethnicity and clinical outcomes among patients treated in the US. 방법 We enrolled hospitalized patients with confirmed COVID-19, oxygen saturation of ≤94% on room air, and radiological evidence of pneumonia. Patients were randomized 1:1 to receive 5d or 10d of intravenous RDV once daily. Among US patients, we examined rates of all-cause mortality, ≥2-point clinical improvement (on a 7-point scale ranging from discharge to death), and discharge across subgroups of patients who self-identified as non-Hispanic white (NHW), Black, Hispanic White (HW), or Asian, or Other. 결과 Overall, 397 patients received RDV, of which 229 (58%) were enrolled in the US. Of these 43 (19%) were Black, 17 (7%) HW, 18 (8%) Asian, 119 (52%) NHW, and 32 (14%) Other. At day 14, rates of clinical improvement were 84% in Black, 76% in HW, 67% in Asian, 67% in NHW, and 63% in Other (Figure). After adjustment for baseline factors, including oxygen support, demographics, and comorbidities, rate of clinical improvement was significantly higher in Black vs NHW patients (p<0.05). Pairwise differences between other race/ethnicity groups and clinical improvement, and between any of the race/ethnicity groups and either mortality or discharge, did not rise to the level of statistical significance. 결론 Our findings demonstrate that in severe COVID-19 patients treated with RDV in the US, traditionally marginalized racial/ethnic groups do not have worse clinical outcomes compared to other groups. Access to care remains an important issue and must be investigated further as a potential source of disparity with regard to COVID-19 outcomes. [ABSTRACT FROM AUTHOR]